The US Patent and Trade Office (USPTO) has awarded Aegis Therapeutics US Patent No. 8,772,231 for “dramatically stabilized insulin formulations suitable for metered nasal spray delivery or injection based upon Aegis’ patented Intravail transmucosal absorption enhancer and ProTek protein stabilization technologies,” the company said.
According to Aegis, the company has conducted a proof of concept study to demonstrate that its “shirt pocket” insulin formulation, which is stable for a minimum of 90 days at 37 C and under agitation, is suitable for delivery by metered dose nasal spray.
The company is looking to license the both the insulin formulation and an intranasal octreotide for the reduction of growth hormone and IGF-I in the blood in patients with conditions such as acromegaly and carcinoid tumors.
Read the Aegis press release on the insulin patent.
Read the Aegis press release on the octreotide license.
